Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $766.45 million
P/E Ratio 26.44
Dividend Yield 0.33%
Shares Outstanding 50.13 million
Earnings per share 0.573
Dividend per share 0.05
Year To Date Return -5.31%
Earnings Yield 3.78%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    Man waves goodbye while looking at computer sitting at desk.
    Share Market News

    8 ASX 200 shares got kicked out of the index on Monday. How are they tracking?

    The S&P Dow Jones Indices quarterly rebalance saw eight shares depart the ASX 200 on Monday.

    Read more »

    A woman sits with her hands covering her eyes while lifting her spectacles sitting at a computer on a desk in an office setting.
    Share Gainers

    Why Accent, Bigtincan, Clinuvel, and IVE shares are dropping today

    These ASX shares are in the red today...

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Clinuvel, EML, Infomedia, and Link shares are dropping today

    These ASX shares are falling on Monday...

    Read more »

    Woman looking at a phone with stock market bars in the background.
    Share Market News

    The ASX 200 is getting a shakeup today. Here's the tea

    The ASX 200 is changing today. Here's what you need to know.

    Read more »

    A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
    Share Market News

    Out in the cold: How are the ASX 200 evictees faring on Monday?

    Here's how these shares are faring after being kicked out of the ASX 200...

    Read more »

    A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These 10 ASX 200 shares outperformed all others on Tuesday.

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ASX 200 shares started the week off on the right foot.

    Read more »

    Share Market News

    Here are the top 10 ASX 200 shares today

    Tech shares led the ASX 200 on Thursday.

    Read more »

    A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
    Investing Strategies

    Why these 3 ASX shares could be in for a massive boost this month

    Also, why there could be more bad news coming for Zip shareholders.

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ASX 200 shares ended the week on a high.

    Read more »

    Five people are leaping in the shallows of the beach water as sunset shines gold on them.
    Share Gainers

    It's a cloudy day on the ASX, but some All Ords shares are still shining brightly

    These shares are defying the market's struggles to post notable gains on Friday.

    Read more »

    A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
    Share Gainers

    3 ASX All Ords shares that leapt over 10% today

    These All Ords shares were on fire today.

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2023 $0.0500 100.00% Final 20 Sep 2023
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.

     

    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    18 Apr 2024 $15.29 $0.14 0.92% 62,525 $15.00 $15.30 $14.94
    17 Apr 2024 $15.15 $0.00 0.00% 58,904 $15.08 $15.35 $15.07
    16 Apr 2024 $15.15 $-0.05 -0.33% 74,156 $15.08 $15.19 $14.95
    15 Apr 2024 $15.20 $0.10 0.66% 77,148 $15.21 $15.37 $14.89
    12 Apr 2024 $15.10 $-0.18 -1.18% 45,013 $15.13 $15.37 $15.05
    11 Apr 2024 $15.28 $-0.10 -0.65% 198,513 $15.13 $15.45 $14.96
    10 Apr 2024 $15.38 $0.13 0.85% 77,525 $15.25 $15.70 $15.22
    09 Apr 2024 $15.25 $-0.36 -2.31% 466,518 $15.46 $15.64 $14.99
    08 Apr 2024 $15.61 $-0.32 -2.01% 137,671 $15.94 $15.97 $15.46
    05 Apr 2024 $15.93 $-0.02 -0.13% 222,280 $15.73 $16.04 $15.50
    04 Apr 2024 $15.95 $-0.23 -1.42% 210,352 $16.18 $16.19 $15.91
    03 Apr 2024 $16.18 $0.58 3.72% 307,427 $15.70 $16.43 $15.65
    02 Apr 2024 $15.60 $1.24 8.64% 299,715 $14.40 $15.72 $14.40
    28 Mar 2024 $14.36 $0.18 1.27% 84,624 $14.08 $14.60 $14.03
    27 Mar 2024 $14.18 $0.43 3.13% 81,515 $13.96 $14.20 $13.85
    26 Mar 2024 $13.75 $0.10 0.73% 111,836 $13.64 $13.84 $13.53
    25 Mar 2024 $13.65 $-0.15 -1.09% 87,416 $13.99 $13.99 $13.57
    22 Mar 2024 $13.80 $-0.35 -2.47% 90,057 $14.19 $14.24 $13.72
    21 Mar 2024 $14.15 $0.48 3.51% 86,567 $14.00 $14.22 $13.80
    20 Mar 2024 $13.67 $-0.10 -0.73% 73,993 $13.75 $13.79 $13.53

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Philippe Wolgen Exercise 301,125 $5,119,125
    Conversion of securities.
    24 Nov 2023 Philippe Wolgen Buy 301,125 $5,119,125
    Conversion of securities.
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    24 Nov 2023 Philippe Wolgen Expiry 1,212,625 $20,614,625
    As advised by the company. Lapsed, 3,01,125 Rights
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    19 Sep 2023 Philippe Wolgen Buy 1,850 $29,813
    On-market trade.
    26 Jun 2023 Philippe Wolgen Transfer 3,120,715 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares
    26 Jun 2023 Philippe Wolgen Transfer 3,120,715 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares
    26 Jun 2023 Philippe Wolgen Buy 1,532 $27,147
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
    Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
    Dr Jeffrey Rosenfeld Non-Executive ChairmanNon-Executive Director Nov 2019
    Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
    Mr Darren Keamy Chief Finance OfficerCompany Secretary Dec 2005
    -
    Darren Keamy Chief Finance OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Ltd 11,280,990 22.83%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 5,679,762 11.50%
    BNP Paribas Nominees Pty Ltd 5,312,764 10.75%
    J P Morgan Nominees Australia Pty Ltd 4,390,776 8.89%
    Dr Philippe Jacques Wolgen 3,122,247 6.32%
    Citicorp Nominees Pty Ltd 3,014,759 6.10%
    Ender 1 LLC 2,590,824 5.24%
    BNP Paribas Nominees Pty Ltd (ii) 1,482,356 3.00%
    Emilino Group Pty Ltd 603,447 1.22%
    National Nominees Ltd 548,371 1.11%
    Dr Mark Edwin Badcock 440,085 0.89%
    Mr David William Trevorrow 229,600 0.46%
    Mr David John Lewis 187,000 0.38%
    HSBC Custody Nominees (Australia) Ltd a/c 2 180,199 0.36%
    Mr Trent Sheldon Redding 179,480 0.36%
    Mr Darren Michael Keamy 178,588 0.36%
    Rusty Hammer Pty Ltd 156,892 0.32%
    Dr Dennis Wright 156,874 0.32%
    Mr Simon John Bown 146,000 0.30%
    BNP Paribas Noms (NZ) Ltd 130,710 0.26%

    Profile

    since

    Note